"We believe that the company's comprehensive suite of solutions, along with its deep relationships with state governments, have positioned it well to procure new business opportunities in the future," Barclays noted.
Centene estimated that if the company wins no new business, 2016 revenue would be at least $24 billion, or up more than 14% from current 2015 guidance, according to the analyst note.
Additionally, Barclays raised its 2015 earnings estimate to $2.75 per share from $2.65, and its 2016 estimate to $3.25 earnings per share from $3.10.
Centene is a healthcare company that offers government-sponsored healthcare programs by assisting in accessing care, coordinating referrals to related health services, and providing education and outreach programs.
Shares of Centene are down 0.25% to $75.20 in morning trading on Monday.
Separately, TheStreet Ratings team rates CENTENE CORP as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
"We rate CENTENE CORP (CNC) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- The revenue growth greatly exceeded the industry average of 13.1%. Since the same quarter one year prior, revenues rose by 48.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- CENTENE CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CENTENE CORP increased its bottom line by earning $2.22 versus $1.43 in the prior year. This year, the market expects an improvement in earnings ($2.70 versus $2.22).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 91.0% when compared to the same quarter one year prior, rising from $32.98 million to $63.00 million.
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Providers & Services industry and the overall market, CENTENE CORP's return on equity exceeds that of both the industry average and the S&P 500.
- Powered by its strong earnings growth of 82.45% and other important driving factors, this stock has surged by 104.09% over the past year, outperforming the rise in the S&P 500 Index during the same period. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
- You can view the full analysis from the report here: CNC Ratings Report